Renal Cancer - Results from #20

Predictive Impact of Early Changes in Serum C-reactive Protein Levels in Nivolumab plus Ipilimumab Therapy for Metastatic Renal Cell Carcinoma - Beyond the Abstract February 8, 2022

Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial - Beyond the Abstract January 28, 2022

p53 Is Functionally Inhibited in Clear Cell Renal Cell Carcinoma (ccRCC): A Mechanistic and Correlative Investigation into Genetic and Molecular Characteristics - Beyond the Abstract December 7, 2021

Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy - Beyond the Abstract November 29, 2021

Association of Baseline Neutrophil-to-Eosinophil Ratio with Response to Nivolumab plus Ipilimumab in Patients with Metastatic Renal Cell Carcinoma - Beyond the Abstract November 22, 2021

Clinical Outcome of Renal Cancer Patients Who Early Interrupted Immunotherapy Due to Serious Immune-Related Adverse Events. Meet-Uro 13 Trial on Behalf of the MeetUro Investigators - Beyond the Abstract October 12, 2021

Immune-Based Combinations for the Treatment of Metastatic Renal Cell Carcinoma: A Meta-Analysis of Randomised Clinical Trials - Beyond the Abstract October 7, 2021

Outcomes of Ureteroscopy and Laser Stone Fragmentation (URSL) for Kidney Stone Disease (KSD): Comparative Cohort Study Using MOSES Technology 60 W Laser System versus Regular Holmium 20 W Laser - Beyond the Abstract September 24, 2021

Pancreatic Metastases in Advanced Renal Cell Carcinoma: An Evolving Prognostic Paradox - Beyond the Abstract September 23, 2021

Efficacy of Immune-Checkpoint Inhibitors (ICI) in the Treatment of Older Adults with Metastatic Renal Cell Carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) Analysis - Beyond the Abstract September 21, 2021

Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent - Beyond the Abstract September 21, 2021

TRIM63 Is a Sensitive and Specific Biomarker for MiT Family Aberration-Associated Renal Cell Carcinoma - Beyond the Abstract August 5, 2021

PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer - Beyond the Abstract July 28, 2021

Irreversible Electroporation for the Treatment of Small Renal Masses: 5-Year Outcomes - Beyond the Abstract July 22, 2021

Selective Suturing or Sutureless Technique in Robot-assisted Partial Nephrectomy: Results from a Propensity-score Matched Analysis - Beyond the Abstract July 19, 2021

Pegilodecakin for Metastatic Renal Cell Carcinoma - Beyond the Abstract June 24, 2021

Does Reduced Renal Function Predispose to Cancer-specific Mortality from Renal Cell Carcinoma? - Beyond the Abstract June 17, 2021

Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-Institutional Registry (REMARCC) - Beyond the Abstract May 18, 2021

Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aN0M0 Renal Cell Carcinoma Patients - Beyond the Abstract May 11, 2021

HIF2-Plk1, an Oncogenic Pathway in Clear Cell Renal Cell Carcinoma - Beyond the Abstract May 3, 2021

Page 2 of 14

email news signup